Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (JNJ)
NYSE:JNJ
JNJ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$140.68 - $181.16
Previous CloseN/A
Volume3.80M
Average Volume (3M)8.30M
Market Cap
$426.69B
Enterprise Value$400.58B
Total Cash (Recent Filing)$18.88B
Total Debt (Recent Filing)$50.76B
Price to Earnings (P/E)18.9
Beta0.22
Next Earnings
Oct 14, 2025EPS Estimate
2.75Last Dividend Ex-Date
Aug 26, 2025Dividend Yield2.85%
Share Statistics
EPS (TTM)2.77
Shares Outstanding2,408,338,900
10 Day Avg. Volume8,066,487
30 Day Avg. Volume8,296,469
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue4.42
Enterprise Value/Gross Profit6.51
Enterprise Value/Ebitda12.00
Forecast
1Y Price Target
$180.06Price Target Upside1.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Bulls Say, Bears Say
Bulls Say
EarningsThe Q2 earnings per share exceeded expectations and the company raised its guidance for 2025.
Market ExpansionThe expansion of the orphan drug exclusion from IRA price negotiations appears to have positive implications for Darzalex FASPRO’s protection from IRA price negotiations.
Product DevelopmentJohnson & Johnson expects its sales growth to accelerate driven by new product launches and strong business momentum.
Bears Say
Margin ConcernsThere is uncertainty around margin accretion due to tariff and MFN concerns.
Tax ImplicationsOperating leverage was slightly diluted by higher tax implications.
Johnson & Johnson News
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $140.68 and its highest was $181.16 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $426.69B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Oct 14, 2025 which is in 40 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Jul 16, 2025. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.682 by $0.088.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of $1.3 which represents an annual dividend yield of 2.85%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.75.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,408,338,900 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.77 in its last earnings report, beating expectations of $2.682. Following the earnings report the stock price went up 6.193%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in JNJ
Johnson & Johnson Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$180.06 (1.12% Upside)
$180.06 (1.12% Upside)
Blogger Sentiment
Bullish
JNJ Sentiment 95%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 704.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $28.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.82%
12-Months-Change
Fundamentals
Return on Equity
30.21%
Trailing 12-Months
Asset Growth
6.79%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson (JNJ) is a multinational corporation founded in 1886, known for its diverse range of healthcare products and services. The company operates through three main sectors: Consumer Health, Pharmaceutical, and Medical Devices. Its portfolio includes well-known consumer products such as baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals. In the pharmaceutical sector, JNJ develops innovative treatments across various therapeutic areas, including immunology, oncology, neuroscience, and infectious diseases. The Medical Devices segment offers a wide array of products used in surgical, orthopedic, and interventional procedures, making JNJ a key player in the global healthcare market.
JNJ Company Deck
JNJ Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in several key areas, including oncology and medtech, alongside raised guidance. However, challenges such as the impact of STELARA's loss of exclusivity and a decline in the orthopedics segment were noted. The overall sentiment is cautiously optimistic, with strong growth prospects and some areas needing improvement.View all JNJ earnings summariesJNJ Sales Breakdown
64.13% Innovative Medicine
35.87% MedTech
JNJ Stock 12 Month Forecast
Average Price Target
$180.06
▲(1.12% Upside)
Technical Analysis
Ownership Overview
0.04% Insiders
18.42% Mutual Funds
13.55% Other Institutional Investors
45.73% Public Companies and Individual Investors